In the final episode, 'From Knowledge to Action: Final Takeaways for Oncology Pharmacists Implementing Bispecific Therapy,' the panelists explored the following critical question:
In Outpatient Bispecific Initiation: Emerging Trends, Eligibility Criteria, and Operational Readiness, our panel of experts address a critical question.
In this episode, 'Sequencing in Focus: Pharmacists Reflect on the Impacts of MajesTEC-3 and MajesTEC-9 Data in Myeloma,' the oncology pharmacists explore the following questions:
This episode, titled 'Availability, Patient Preference, and Linvoseltamab: What Pharmacists Need to Know About the Evolving Bispecific Landscape,' features oncology pharmacists discussing the following critical questions:
In 'Patient Selection and Line-of-Therapy Navigation: Practical Insights for a Complex Myeloma Treatment Landscape,' our panel of experts delve into the following critical questions:
In this episode, 'The Long-Term Infection Risk: How Pharmacists Are Approaching Prophylaxis and Monitoring in Bispecific Myeloma Care,' the oncology pharmacists explore the following questions:
In this episode, 'From Treatment to Prevention: How Pharmacists Are Refining CRS Management for Bispecific Antibody Therapy,' the oncology pharmacists explore the following questions:
In 'Getting CRS Right: Clinical Presentation, Appropriate Response, and Building a Well-Educated Care Team,' our panel of experts delve into the following critical questions:
In this episode, 'Reducing Hospitalization Without Compromising Safety: Step-Up Dosing Criteria and Best Practices in Myeloma,' the oncology pharmacists explore the following questions:
In 'Pharmacists at the Center: Managing REMS Education, Compliance, and Collaboration Across Care Settings,' our panel of experts delve into the following critical question:
This episode, titled 'Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs,' features oncology pharmacists discussing the following critical question:
In 'Remote Patient Monitoring in Myeloma: How Technology Is Transforming Bispecific Antibody Management,' our panel of experts delve into the following critical question:
In this episode, 'When Transitions Break Down: Real-World Challenges and Lessons Learned in Myeloma Care Handoffs,' the oncology pharmacists explore the following question:
This episode, titled 'Roles, Resources, and Relationships: The Stakeholder Framework Behind Successful Myeloma Care Transitions,' features oncology pharmacists discussing the following critical questions:
In 'When It Works: Best-Case Scenarios and Lessons Learned From Successful Care Transitions in Myeloma,' our panel of experts delve into the following critical question:
In this episode, 'Planning Before the First Dose: Pre-Treatment Transition Strategies for Bispecific Antibody Therapy in Myeloma,' the oncology pharmacists explore the following question:
1. Transition planning needs to begin before the first dose is administered, not after step-up dosing is complete. What does that pre-treatment planning look like at your institution?
Welcome back to another Pharmacy Times Practice Pearls series. In this episode, titled "Transitions of Care in Multiple Myeloma: Why Handoffs Remain the Biggest Operational Challenge," Zahra Mahmoudjafari led the conversation about the following question: Transitions of care are the single most consistent operational challenge, outranking efficacy and safety concerns. Why are they difficult, and where are the pain points?
Adherence classes were determined for patients taking multiple medications (ie, lipid-lowering, antihypertensive, antidiabetic) and were found to be related to serum profiles and risk of adverse events.
